Treatment of dry age-related macular degeneration

Marco A. Zarbin, Philip J Rosenfeld

Research output: Chapter in Book/Report/Conference proceedingChapter


We have entered the era of pathwaybased therapy for the early and late manifestations of AMD. Each of the treatments mentioned in this chapter acts at a putative step in the pathogenesis of AMD. Steps that have been targeted thus far include oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β -amyloid accumulation), and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e. drug resistance), and less frequent treatment.

Original languageEnglish (US)
Title of host publicationMedical Retina
PublisherS. Karger AG
Number of pages9
ISBN (Print)9783805599917, 9783805599900
StatePublished - May 24 2012
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)


Dive into the research topics of 'Treatment of dry age-related macular degeneration'. Together they form a unique fingerprint.

Cite this